Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.36 USD
Change Today -0.03 / -0.88%
Volume 7.4K
AXGN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

axogen inc (AXGN) Key Developments

AxoGen, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 04:30 PM

AxoGen, Inc. Presents at Canaccord Genuity 10th Annual Musculoskeletal Conference, Mar-24-2015 04:30 PM. Venue: MGM Grand Hotel, Las Vegas, Nevada, United States.

AxoGen, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for 2015

AxoGen, Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, revenues totaled $4.79 million, a 61% increase compared to $2.98 million in the prior year fourth quarter. Net loss was $6.5 million or $0.35 per share compared to net loss of $4.1 million or $0.24 per share for the fourth quarter of 2013. For the year, revenues were $16,817,403 against $10,947,361 a year ago. Loss from operations was $9,800,790 against $9,592,205 a year ago. Net Loss available to common shareholders was $17,710,476 against $14,556,885 a year ago. Basic and diluted loss per share was $0.99 against $1.08 a year ago. Net cash used for operating activities was $10,451,059 against $10,444,758 a year ago. Purchase of property and equipment was $542,045 against $178,776 a year ago. Acquisition of intangible assets was $52,002 against $65,189 a year ago. Based on the market's increasing awareness of the company's product portfolio, continued expansion of its sales footprint and current sales pipeline, the company currently anticipates 2015 full year revenue to exceed $24 million and annual gross margin in the mid to high 70% range.

AxoGen, Inc. to Report Q4, 2014 Results on Mar 05, 2015

AxoGen, Inc. announced that they will report Q4, 2014 results After-Market on Mar 05, 2015

AxoGen, Inc., Q4 2014 Earnings Call, Mar 06, 2015

AxoGen, Inc., Q4 2014 Earnings Call, Mar 06, 2015

AxoGen, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2014

AxoGen, Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2014. For the quarter, the company expected revenue of $4.79 million, a 61% increase compared to revenue of $2.98 million in the fourth quarter of 2013. For the full year 2014, revenue is expected to be $16.8 million, representing a 54% increase compared to revenue of $10.9 million for the full year ended December 31, 2013. These preliminary results are based on currently available financial and operating information and management's preliminary analysis of the unaudited financial results for the quarter and year ended December 31, 2014 and are subject to finalization in connection with the preparation of the company’s audited financial statements.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AXGN:US $3.36 USD -0.03

AXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $71.14 USD -0.37
Integra LifeSciences Holdings Corp $61.31 USD +0.84
Stryker Corp $96.90 USD -0.28
View Industry Companies
 

Industry Analysis

AXGN

Industry Average

Valuation AXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AXOGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.